AtriCure (ATRC) Misses Q3 EPS by 6c

AtriCure (NASDAQ: ATRC) reported Q3 EPS of ($0.33), $0.06 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $56.6 million versus the consensus estimate of $55.23 million.

GUIDANCE:

Management is updating revenue guidance for 2019 to a range of $227 million to $229 million, corresponding to growth of 13% to 14% for the year, and maintaining expectations for a full-year adjusted EBITDA loss between $7 million and $9 million. The consensus is $227.5 million.

For earnings history and earnings-related data on AtriCure (ATRC) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c